Related Experiment Videos
[Lymphoma with bladder involvement and renal transplantation]
1Service d'Urologie et de Transplantation, Hôpital Edouard Herriot, Lyon.
Summary
Intensive immunosuppression in renal transplant recipients may drive B cell lymphomas, often linked to Epstein-Barr virus. Early bladder tumor resection and reduced immunosuppression offer better outcomes than traditional therapies.
Area of Science:
- Oncology
- Immunology
- Transplantation
Background:
- Post-transplantation lymphoproliferative syndromes (PTLS) are serious complications following organ transplantation.
- Intensive immunosuppressive protocols are often necessary but increase the risk of PTLS.
- Epstein-Barr virus (EBV) is a known cofactor in the development of these lymphomas.
Observation:
- A case of a renal transplant recipient developed a monoclonal B cell lymphoma with plasma cell differentiation in the bladder.
- The bladder is an uncommon site for PTLS.
- Diagnosis involved endoscopic resection and immunohistochemical analysis.
Findings:
- Early-stage bladder PTLS may be treated effectively with tumor resection and reduced immunosuppression.
- Advanced stages require more aggressive treatment strategies.
- Anti-B lymphocyte monoclonal antibodies (targeting CD21, CD24) show efficacy, particularly in EBV-related polyclonal PTLS.
- Anti-CD38 monoclonal antibodies are a promising investigational therapy.
- Conventional chemotherapy and radiotherapy have yielded disappointing results.
Implications:
- This case highlights the critical role of immunosuppression intensity in PTLS development.
- It underscores the importance of considering rare tumor sites like the bladder in transplant recipients.
- Novel therapeutic approaches, including targeted monoclonal antibodies, offer improved prospects for managing PTLS.
- Further research into anti-CD38 therapies is warranted.